Cargando…

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Detalles Bibliográficos
Autores principales:	Anderson, Roy M, Vegvari, Carolin, Truscott, James, Collyer, Benjamin S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836302/ https://www.ncbi.nlm.nih.gov/pubmed/33159850 http://dx.doi.org/10.1016/S0140-6736(20)32318-7

Ejemplares similares

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

Spatial scales in human movement between reservoirs of infection
por: Hardwick, Robert J., et al.
Publicado: (2021)

Herd immunity or health equity? – extending HPV vaccination
por: Keddy, Karen H., et al.
Publicado: (2023)

COVID-19 herd immunity by immunisation: are children in the herd?
por: Obaro, Stephen
Publicado: (2021)

Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

COVID-19 herd immunity: where are we?
por: Fontanet, Arnaud, et al.
Publicado: (2020)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Cas9 immunity creates challenges for CRISPR gene editing therapies
por: Crudele, Julie M., et al.
Publicado: (2018)

Herd immunity: hyperimmune globulins for the 21st century
por: Elliott, Sarah TC, et al.
Publicado: (2018)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Human population movement can impede the elimination of soil-transmitted helminth transmission in regions with heterogeneity in mass drug administration coverage and transmission potential between villages: a metapopulation analysis
por: Vegvari, Carolin, et al.
Publicado: (2019)

SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties
por: Oliu-Barton, Miquel, et al.
Publicado: (2021)

Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
por: Shenoy, Padmanabha, et al.
Publicado: (2022)

Natural immunity helps overcome the age-related decline of SARS-CoV-2 vaccine immunogenicity
por: Verschoor, Chris P, et al.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Immunological considerations for SARS-CoV-2 human challenge studies
por: Douglas, Alexander D., et al.
Publicado: (2020)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD
por: Otten, Antonius T, et al.
Publicado: (2023)

Reaching the theoretical herd immunity threshold in Iquitos, Peru: are seroprevalence data enough?
por: Chenet, Stella M, et al.
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
por: Sette, Alessandro, et al.
Publicado: (2020)

Endemic SARS-CoV-2 will maintain post-pandemic immunity
por: Veldhoen, Marc, et al.
Publicado: (2021)

SARS-CoV-2 immunity and HIV infection: total recall?
por: Dauby, Nicolas, et al.
Publicado: (2021)

Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration
por: Kura, Klodeta, et al.
Publicado: (2020)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_55k4uk1v33tnodc7o82bipe703